Conclusion: Our study demonstrates the clinical benefit of anti-programmed death-1 therapy with pembrolizumab among patients with previously treated unresectable or metastatic MSI-H/dMMR noncolorectal cancer. Toxicity was consistent with previous experience of pembrolizumab monotherapy.
A Communication must convey the scientific findings concisely in abstract, main text, and graphical elements as determined by word count not exceeding 2200 words, including titles/footnotes/captions of approximately five graphics (typically 2 inches long in a single column). References are not included in word count to allow article titles to be included at submission. All graphics and tables must be placed near the point of first mention in the text of the manuscript (not grouped at the end of the document) and must be sized according to current guidance. Long notes are not permitted in the References section; information not directly germane to the Communication can be included as Supporting Information.
The cover letter should provide explicit assurance that the manuscript is not under consideration for publication and has not been published elsewhere. Please note any use of a preprint server in the cover letter and include a link to the preprint, and as appropriate, state how the manuscript has been adjusted/updated between deposition and submission.
Author List. Include as coauthors all those who have made substantial contributions to the work. Use first names, initials, and surnames (e.g., John R. Smith). Do not use only initials with surnames (e.g., J. R. Smith), because this causes indexing and retrieval difficulties and interferes with unique identification of an author. Deceased persons who meet the criteria for inclusion as coauthors should be so included, with an Author Information note indicating the date of death. Do not include professional or official titles or academic degrees. At least one, or optionally more than one author must be designated with an asterisk as the author(s) to whom reader correspondence regarding the published manuscript may be addressed.
Institution Address. The author affiliation(s) listed should be the institution(s) where the work was conducted. If the present address of an author differs from that at which the work was done, that address should be given in an Author Information note.
Acknowledgment. Dedications and notes acknowledging financial or professional assistance to the conduct of research or indicating presentation at a meeting should be brief and placed in the Acknowledgment section.
Author Information Notes. The e-mail address(es) of the corresponding author or authors must be provided as a Corresponding Author note. Present addresses for individual authors that differ from the address(es) at which the work was done should be given in a Present Addresses note.
Simple equal authorship statements are allowed and may be presented in an Author Contribution note. However, itemization of individual author contributions or partial authorship is not permitted in any part of the manuscript or Supporting Information.
References and Footnotes. All the references and footnotes must be placed together in a list at the end of the manuscript text. In the Web edition, many of them will have links to other Web resources, such as the corresponding abstracts in Chemical Abstracts and the full text on publisher Web sites. Because of this electronic linking, and to aid scientific research, it is crucial that authors verify the accuracy of all reference citations and footnotes.
Unnecessarily long lists of references should be avoided, and excessive self-citation is not permitted. However, authors must reference all previous publications in which portions of the present work have appeared. Literature references and short explanatory footnotes must be numbered with Arabic numerals in the order of their first citation in the text and the corresponding numbers placed at the appropriate locations in the text as superscripted numerals.
Long footnotes should be avoided in Articles and are not permitted in Communications; additional data and peripheral discussion should be placed in the Supporting Information rather than in footnotes. Supplementary references may be placed in Supporting Information.
Paramagnetic compounds of this category present a further complication if NMR spectroscopy does not furnish clear evidence for the proposed formulation (note that NMR spectroscopy of paramagnetic complexes can be useful if sufficiently large sweep widths are used). In many cases, X-ray diffraction may provide the most unambiguous characterization of such complexes, but this will not suffice as the only means of characterization. In the absence of an X-ray structure determination, evidence for elemental constitution must be provided by elemental analysis (e.g., combustion analysis, microprobe analysis), or mass spectrometry. Magnetic moment and/or ESR spectroscopic data should also be given for paramagnetic compounds if it is considered that the spin state of the molecule is of especial interest.
Computations. When computational results are an essential part of a manuscript, sufficient detail must be given, either within the paper or in the Supporting Information, to enable readers to reproduce the calculations. This includes data such as force field parameters and equations defining the model (or references to where such material is available in the open literature). If the software used for calculations is generally available, it must be properly cited in the References and Footnotes. References to the methods upon which the software is based must also be provided. Results obtained from methods or parameters that are not adequately described in the manuscript or in the literature are not acceptable for publication. Authors who report the results of electronic structure calculations are requested to provide as Supporting Information the geometries (either as Cartesian coordinates or Z matrices) of all the stationary points whose relative energies are given in the manuscript. The absolute energies in hartrees that are computed at these geometries should not be given in the manuscript but should be included in the Supporting Information. Where applicable, the number of imaginary frequencies should be reported to identify stable structures and transition states.
Journal of the American Chemical Society authors may deposit an initial draft of their manuscript in a preprint service such as ChemRxiv, bioRxiv, arXiv, or the applicable repository for their discipline before the manuscript is accepted for publication in JACS. Authors may revise the preprint version of their manuscript up until a final acceptance decision has been issued. Please note any use of a preprint server in the cover letter and include a link to the preprint, and as appropriate, state how the manuscript has been adjusted/updated between deposition and submission. All other prior/redundant publication is forbidden. Upon publication in JACS, authors should add a link from the preprint to the published article via the Digital Object Identifier (DOI). Some preprint servers, including ChemRxiv and bioRxiv, add this link for authors automatically after publication. For further details, contact the Editorial Office. For the ACS Publications policy on theses and dissertations, click here.
During manuscript submission, the submitting author must provide contact information (full name, email address, institutional affiliation, and mailing address) for all of the coauthors. Because all of the author names are automatically imported into the electronic Journal Publishing Agreement, the names must be entered into ACS Paragon Plus. (Note that coauthors are not required to register in ACS Paragon Plus.) Author affiliation should reflect where the work was completed, even if the author has since left that institution. Authors may include a note with a current address if their institution has changed since the work was completed.
Each table must have a brief (one phrase or sentence) title that describes the contents. The title should be understandable without reference to the text. Details should be put in footnotes, not in the title. Tables should be used when the data cannot be presented clearly in the narrative, when many numbers must be presented, or when more meaningful inter-relationships can be conveyed by the tabular format. Tables should supplement, not duplicate, information presented in the text and figures. Tables should be simple and concise.
Progression-free survival is defined as the interval between the first treatment day (in phase 3 trials: day of randomization for intent-to-treat analysis) to the first sign of disease progression or death from any cause. Event-free survival is defined as the interval between the first treatment day (in phase 3 trials: day of randomization for intent-to-treat analysis) to the first sign of disease progression or start of a new treatment or withdrawal from the trial because of toxicity or death (whichever occurs first). Overall survival is defined as the interval between the first treatment day (in phase 3 trials: day of randomization for intent-to-treat analysis) to death. Time to next treatment is defined as interval between the first treatment day until the patient starts an alternative therapy for progressive CLL.
Patients with CLL are at increased risk for infection because of compromised immune function, which might be related to the disease itself and/or to the consequences of therapy. Nevertheless, the rate of infection following treatment can be used in assessing the relative immune-suppressive effects of a given therapy. The etiology of the infection should be reported and categorized as bacterial, viral, or fungal, and as proven or probable. The severity of infections should be quantified as minor (requiring either oral antimicrobial therapy or symptomatic care alone), major (requiring hospitalization and systemic antimicrobial therapy), or fatal (death as a result of the infection). 2b1af7f3a8